PCA
TRIB

Prospect Capital Advisors’s Trinity Biotech TRIB Stock Holding History

Prospect Capital Advisors’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-81,880
Closed -$5.41M – 24
2016
Q3 		$5.41M Buy
81,880
+6,200
+8% +$386K 3.94% 13
2016
Q2 		$4.29M Buy
75,680
+8,370
+12% +$472K 3.81% 14
2016
Q1 		$3.92M Buy
+67,310
New +$3.57M 4.65% 12

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Prospect Capital Advisors's TRIB Position: Q4 2016 in Review

Prospect Capital Advisors sold out of Trinity Biotech (TRIB) in Q4 2016, closing a stake of 81,880 shares — an estimated $5.41M sold.

Prospect Capital Advisors first reported a position in TRIB in Q1 2016 and held it in 3 quarters. The position peaked at $5.41M in Q3 2016. 71 funds tracked by Wall St. Rank hold TRIB as of Q4 2016.

  • Prospect Capital Advisors reported no remaining Trinity Biotech position as of Q4 2016 after selling out during the quarter.
  • Prospect Capital Advisors sold 81,880 Trinity Biotech shares in Q4 2016, an estimated $5.41M.
  • Prospect Capital Advisors first reported a position in Trinity Biotech in Q1 2016 and held it in 3 quarters.
  • Prospect Capital Advisors's Trinity Biotech position peaked at $5.41M in Q3 2016.
  • 71 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2016.

Based on Prospect Capital Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.